The Company will Focus on Pre-Clinical Facilitation of Target Validation Proof of Concept of TAT Inhibition, Structure Activity Relationships for Compound Identification Based on Fragment Lead Discovery through Collaborations with Leading Scientific Institutions
COLORADO SPRINGS, Colo., Jun 05, 2012 (BUSINESS WIRE) — Cannabis Science (CBIS.OB) announced today the initiation of a research program to explore the commercial development of Phytocannabinoid-based therapeutics for drug resistant HIV infection. The program will facilitate an antiviral investigation of Phytocannabinoids inhibition of HIV TAT. Cannabis Science is a publicly traded, pioneering U.S. Biotech Company developing pharmaceutical products for global public health challenges.
– New scientific data supports Phytocannabinoid inhibition of HIV TAT
– An initial discovery program will identify structural and medicinal biochemistry of CS-TATI-1 inhibition of TAT
– Formation of a Scientific Advisory Board (SAB) and Collaborative Research and Development Agreement (CRADA) to facilitate initial research
Early Research Provides Clue to New Strategy for Inhibiting HIV Replication
Data published in March by researchers at the Mount Sinai School of Medicine found that cannabinoids inhibit TAT induced migration to TAT via cannabinoid 2 receptors (CB2). Funding for the Mount Sinai study was provided by a National Institutes of Health (NIH) Clinical and Translational Science Award Grant.
Cannabis Science’s research of CS-TATI-1 will be targeted to newly diagnosed patients infected with drug resistant virus, treatment experienced patients with drug-resistant HIV strains, and those intolerant of currently available therapies.
Pathways to market for CS-TATI-1
Cannabis Science will be pursuing a wide range of NIH based Federal Research Programs such as RO1′s, PO1′s and SBIRS which exist to support preclinical development of target validation and proof of concept studies. These studies will be implemented through collaborations with leading scientific institutions. Cannabis Science will also be pursuing other clinical research collaborations including the AIDS Clinical Trials Groups (ACTG), the Canadian AIDS Trial Network (CATN) and the European AIDS Trial Network (EATN).
Dr. Melamede, President and CEO of Cannabis Science Inc., states, “Cannabis Science is dedicated to the development of the first Phytocannabinoid-based treatment for HIV. Our program is based on the initial identification of antiviral activity of Phytocannabinoids against TAT activity. Cannabinoids have demonstrated an inhibitory effect on the progression of HIV expression by interfering with the critical functions of TAT. The Company will pursue various Federal research initiatives that will help fund the initial medicinal chemistry characterization of cannabinoid TAT inhibition.”
Cannabis Science is currently in the process of forming an eminent Scientific Advisory Board (SAB) for the CS-TATI-1 program. The SAB will include several leaders in HIV research and commercial drug development.
About the Global HIV/AIDS Pandemic
HIV’s ability to mutate and reproduce itself even in the presence of antiretroviral drugs, has led to a growing rate of drug resistance. Increasing drug resistance is severely limiting treatment options for HIV patients around the world, increasing direct and indirect health costs, furthering the spread of drug resistant strains of HIV and is creating a pressing need to develop new HIV drugs.
The U.S. government invests billions of dollars a year in HIV/AIDS research, treatment and care through a variety of programs. The Ryan White CARE Act, which funds the treatment and care of people living with HIV in the U.S., totals $2.3 billion a year. Among its many other contributions to fighting HIV/AIDS globally, the U.S. provides $22.8 million annually to The U.S. Military HIV Research Program and approximately $1 billion per year to The Global Fund to Fight AIDS, Tuberculosis and Malaria.
Pharmaceutical sales to treat HIV equal US $10.6 billion annually. Treatment cost per patient in the U.S. for HIV antivirals alone is approximately US $15,000 a year.
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of cannabinoid research and development for unmet medical needs. The Company works with leading experts in HIV drug development, medicinal characterization, and clinical research to develop, produce, and commercialize Phytocannabinoid-based pharmaceutical products.
Cannabis Science is currently working with CBR International to develop a Pre-IND Application to the FDA that focuses on the use of CS-S/BCC-1 topical cannabis-based preparations for the treatment of basal and squamous cell carcinomas.
Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as “anticipate,” “seek,” intend,” “believe,” “plan,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.